Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis

We aimed to evaluate the effectiveness or efficacy of heterologous or homologous COVID-19 vaccine regimens against COVID-19-related outcomes after primary immunization with two doses of CoronaVac or Sinopharm COVID-19 vaccines. PubMed, EMBASE, Web of Science, and Cochrane Library databases were sear...

Full description

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2023-08, Vol.19 (2), p.2221146
Main Authors: Zhang, Xiaoyin, Xia, Jiayue, Jin, Lairun, Wu, Yanfei, Zheng, Xiuyu, Cao, Xiang, Meng, Xingchen, Li, Jingxin, Zhu, Fengcai
Format: Article
Language:English
Subjects:
Coronavirus – Review
COVID-19
COVID-19 - prevention & control
COVID-19 Vaccines
effectiveness
efficacy
Humans
Immunization
inactivated vaccine
meta-analysis
Review
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We aimed to evaluate the effectiveness or efficacy of heterologous or homologous COVID-19 vaccine regimens against COVID-19-related outcomes after primary immunization with two doses of CoronaVac or Sinopharm COVID-19 vaccines. PubMed, EMBASE, Web of Science, and Cochrane Library databases were searched up to 31 October 2022. The primary measure was vaccine effectiveness against COVID-19 infection with homologous or heterologous booster. The results showed heterologous and homologous booster significantly improved effectiveness against COVID-19 infection compared to primary immunization. The effectiveness against COVID-19 infection was 89.19% (95%CI 78.49, 99.89) for heterologous mRNA vaccine booster, 87.00% (95%CI 82.14, 91.85) for non-replicating vector vaccine booster, 69.99% (95%CI 52.16, 87.82) for homologous booster, and 51.48% (95%CI 41.75, 61.21) for two doses of inactivated vaccine. Homologous and heterologous regimens were also effective against SARS-CoV-2 variants, and more evidence is still needed to confirm our findings.
ISSN:2164-5515
2164-554X
2164-554X
DOI:10.1080/21645515.2023.2221146